Back to top
more

Neuronetics (STIM)

(Delayed Data from NSDQ)

$4.25 USD

4.25
2,167,429

-0.30 (-6.60%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $4.22 -0.03 (-0.59%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -87.50% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -61.54% and 9.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integra LifeSciences (IART) Q1 Earnings Miss Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of -4.65% and 0.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harshit Gupta headshot

BWAY Drops 15% in Four Days: How to Play the Stock Before Earnings?

by Harshit Gupta

BWAY stock continues to struggle near its IPO price despite growth. With rising revenues, global expansion and valuation concerns, is it a buy, hold or sell before earnings?

Zacks Equity Research

Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -26.09% and 3.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 37.80% and 4.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -5.88% and 0.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 46.15% and 5.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

STIM Stock Likely to Gain From Updated TMS Coverage

by Zacks Equity Research

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.

Harshit Gupta headshot

Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments

by Harshit Gupta

Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.

Zacks Equity Research

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

by Zacks Equity Research

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Zacks Equity Research

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Zacks Equity Research

Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -22.22% and 12.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 9.09% and 0.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 1.61% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

by Zacks Equity Research

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

Zacks Equity Research

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

by Zacks Equity Research

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Zacks Equity Research

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

by Zacks Equity Research

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

Zacks Equity Research

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of 26.92% and 2.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of 7.59% and 1.80%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Neuronetics (STIM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.